Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
Abstract Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects up to 70 000 people in the UK and the most common inherited cause of end-stage kidney disease (ESKD). It is generally a late-onset multisystem disorder characterised by bilateral kidney cysts, liver cysts and an increased risk of...
Saved in:
| Main Authors: | Matt Gittus, Helen Haley, Tess Harris, Sarah Borrows, Neal Padmanabhan, Danny Gale, Roslyn Simms, Terri Williams, Aaron Acquaye, Alisa Wong, Melanie Chan, Eduardo Lee, Albert CM Ong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-03960-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5
by: Akinari Sekine, et al.
Published: (2025-06-01) -
Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network
by: Ming-Ju Wu, et al.
Published: (2024-12-01) -
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD
by: F.J. Roca Oporto, et al.
Published: (2024-04-01) -
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
by: Kiyotaka Uchiyama, et al.
Published: (2025-04-01) -
Reactive Oxygen Species in Cystic Kidney Disease
by: Sanat Subhash, et al.
Published: (2024-09-01)